Table 2.
Triala | Baseline | post-M1 | post-M2 | pre-M2 | post-M3 | |
---|---|---|---|---|---|---|
Urea (mM)1 | AA | 4.61 ± 1.72 | 8.20 ± 3.65 | 12.70 ± 4.50* | 13.25 ± 4.10* | 17.56 ± 5.30* |
PL | 4.55 ± 1.90 | 7.36 ± 2.30 | 12.95 ± 5.00* | 9.07 ± 4.00 | 16.92 ± 5.10* | |
Lactate (mM)2 | AA | 2.95 ± 0.77 | 13.38 ± 4.17* | 12.78 ± 3.77 | 2.22 ± 0.53 | 11.93 ± 2.90 |
PL | 3.19 ± 0.75 | 13.37 ± 2.96* | 12.24 ± 3.45 | 2.36 ± 0.55 | 12.57 ± 2.27 | |
Glucose (mM)3 | AA | 5.26 ± 0.28 | 4.39 ± 0.44* | 4.97 ± 0.50 | 5.37 ± 0.39 | 5.12 ± 0.50 |
PL | 5.25 ± 0.44 | 4.20 ± 0.27* | 4.89 ± 0.39 | 5.36 ± 0.22 | 5.28 ± 0.39 | |
Glycerol (μM)4 | AA | 27.75 ± 10.37 | 49.38 ± 22.00 | 76.48 ± 27.14* | 79.81 ± 24.91* | 105.78 ± 31.76* |
PL | 27.42 ± 11.39 | 44.34 ± 13.96 | 78.00 ± 30.22* | 54.65 ± 24.31 | 101.91 ± 30.93* | |
NEFA (mM)b,5 | AA | 0.33 ± 0.17 | 0.21 ± 0.08 | 0.34 ± 0.15 | 0.38 ± 0.12 | 0.47 ± 0.20 |
PL | 0.36 ± 0.16 | 0.21 ± 0.06 | 0.38 ± 0.10 | 0.58 ± 0.24 | 0.55 ± 0.19 | |
RPEc,6 | AA | 9.3 ± 2.0 | 16.0 ± 2.0* | 15.9 ± 2.0* | - | 15.2 ± 3.0* |
PL | 9.3 ± 2.0 | 12.8 ± 2.0* | 13.6 ± 2.0* | - | 14.6 ± 2.0* |
a AA BCAA, arginine, and citruline, PL placebo. b NEFA non-esterified fatty acid. c RPE ratings of perceived exertion. *Significantly different from baseline in the same trial (p < .05)
1Main effects: trial: p = .329; time: p < .001; interaction: p = .167
2Main effects: trial: p = .325; time: p < .001; interaction: p = .165
3Main effects: trial: p = .816; time: p < .001; interaction: p = .520
4Main effects: trial: p = .325; time: p < .001; interaction: p = .165
5Main effects: trial: p = .117; time: p < .001; interaction: p = .213
6Main effects: trial: p = .886; time: p = .003; interaction: p = .718